Study type

Study topic

Human medicinal product
Disease /health condition

Study type

Non-interventional study

Scope of the study

Effectiveness study (incl. comparative)

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cross-sectional
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

BLINATUMOMAB

Medical condition to be studied

Philadelphia chromosome negative
Population studied

Short description of the study population

Physicians, nurses, or pharmacists who have managed, administered, or prepared Blincyto for at least 1 adult patient (≥ 18 years of age at Blincyto initiation) with
Philadephia chromosome-negative relapsed or refractory B-precursor.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

200
Study design details

Main study objective

The primary objectives of the study are to describe the receipt of the Blincyto brochures, and knowledge and behaviours outlined in the Blincyto brochures among physicians, nurses and pharmacists

Outcomes

Proportion of subject who received the brochure, a mean score of knowledge questions answered correctly, a mean score of behavior questions with correct responses, Understanding and usage of the brochures

Data analysis plan

Categorical data will be summarized by counts and percentages. Continuous data will be summarized using number, mean, standard deviation (SD), median, quartiles, minimum and maximum and in the case of non-normally distributed data, median, range and interquartile range. All 95% confidence intervals will be presented to three decimalplaces. The statistical analysis will include a summary of the study conduct, a descriptive analysis and the analysis of the objectives.
Documents
Study results
English (166.62 KB - PDF)View document